Serelaxin (SLX)-based therapy for cardiac hypertrophy and fibrosis: Serelaxin (SLX), a recombinant relaxin-2, decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 24/August/2018, 2.52 pm